Dr. Jan Groen
Chief Executive Officer
Jan Groen joined Intravacc in May 2020 as Chief Executive Officer. Previously Jan was the CEO of Novigenix in Switzerland, a privately held immunotranscriptomic diagnostic company and MDxHealth, a Euronext listed genomic diagnostics company. Jan’s career spans over many years in the global biotech industry. Jan was President and COO of Agendia, co-founder of ViroClinics and DxOrange and he has held management and scientific positions at Focus Diagnostics, the Erasmus Medical Center, National Institute of Public Health and Akzo-Nobel. Currently he is chairman of the board of Cergentis, serves on the board of SPL Medical in the Netherlands, Destina Genomics SA in Spain and Angle Ltd in the UK. He holds a Ph.D. degree in Medical Microbiology from the Erasmus University Rotterdam, and has published over 125 papers in international scientific journals.
Chief Financial Officer
Nathalie is an experienced CFO and finance director for multinational companies with a proven track record of financial and senior-level management primarily in the high tech and healthcare industry. Nathalie joined Intravacc in 2021 from cancer immunotherapies R&D company Gadeta, after having served as their Chief Financial Officer and Managing Director since 2018. Nathalie started her professional career at PricewaterhouseCoopers. She qualified as a certified public accountant in 2001, after which she held various senior positions in several companies. Her previous positions include Head of Finance at U.S. Nasdaq listed Dutch biotech company Merus. She holds a post-doc degree in accountancy from the University of Amsterdam, the Netherlands.
Join our Community
Are you interested in becoming part of an innovative community, to learn alongside top scientists, to work with state-of-the art equipment, to get an inside look of and contribute to the biotech sector, where industry leaders, government, universities and international non-governmental organizations collaborate? Then Intravacc is the place for you.
Subscribe to our news update
Stay up to date with the latest developments, and be the first to receive our news updates and announcements.